US super investors hold £1.4bn worth of this high-flying FTSE 100 stock, according to financial filings.
AstraZeneca (LSE:AZN), a pharma and biotech company, is one of the most popular UK shares for stock market gurus from across the pond.
It’s no surprise considering the stock is second only to Shell in the FTSE 100 index by market cap.
And US investors in charge of multi-billion dollar funds are taking notice of the Anglo-Swedish pharma king.
Who are these super investors? And how have their investments been faring so far?
A hard pill to swallow
Ken Fisher, founder of Fisher Investments, has beaten the return of the S&P 500 index by an average of 4.2% per year over the last two decades.
The skilled stock picker held $1.18bn worth of AstraZeneca shares at the date of his most recent filing. Since his first purchase in 2015, he’s made a net return of 40%.
Super investor
Ken Fisher
Jim Simons
Steven Cohen
Ray Dalio
Ken Griffin
Mario Gabelli
Earliest purchase
2015
2013
2014
2021
2013
2001
Holdings current value
$1,180m
$324m
$109m
$3.9m
$0.729m
$0.568m
Netted
40%
3.6%
-16%
-0.2%
37%
-5%
Source: Data extracted from stockcircle.com
However, this isn’t actually that impressive given the S&P 500 returned 44% over the last five years.
Many of the super investors on the list have even made a loss through holding AstraZeneca stock.
Steven Cohen – who founded the hedge fund Point72 Asset Management – has suffered a 16% loss on his AstraZeneca shares. The investor, who’s also the owner of the New York Mets baseball team, started dealing in AstraZeneca shares in 2014 and currently holds $109m worth.
So should I add AstraZeneca to my portfolio despite these disappointing results?
Pipeline’s looking fine
A major risk for AstraZeneca investors comes in the potential for drug development projects being frustrated by unforeseen obstacles. At the same time, existing products are only protected by patents for a set period. Pharma companies are constantly in a race to get patented products approved to replace those that are expiring.
But given AstraZeneca has a pipeline of 184 projects in development, I believe it could be less exposed to this risk than comparable companies. Pfizer’s pipeline, for example, comprises only 104 projects in development.
The company is also globally diversified. Its Q2 report, for example, shows 36% of revenue came from the US, 30% from emerging markets and 20% from Europe.
Healthcare also tends to stand up well to inflation and recession, the two spectres hanging over investors in 2022. In the words of Confucius: “A healthy man wants a thousand things; a sick man wants one”. That one thing could be an AstraZeneca drug.
However, at a forward price-to-earnings (P/E) ratio of 14, the stock looks expensive compared to peers Merck (with a P/E of 12) and Pfizer (with a P/E of 8). On the other hand, Moderna’s P/E ratio is higher at 21.
I can’t see compelling investment case for my portfolio today. I do want to invest in healthcare, but lack any special insights into pharma technology, so I’d prefer to insulate myself from individual company risks by buying a healthcare ETF.
The post 6 super investors hold this FTSE 100 stock. Should I buy it too? appeared first on The Motley Fool UK.
6 shares that we think could be the biggest winners of the stock market crash
The hotshot analysts at The Motley Fool UK’s flagship share-tipping service Share Advisor have just unveiled what they think could be the six best buys for investors right now.
And while timing isn’t everything, the average return of their previous stock picks shows that it could pay to get in early on their best ideas – particularly in this current climate!
What’s more, all six ‘Best Buys Now’ are available to access right now, in just a few clicks.
Learn more
setButtonColorDefaults(“#5FA85D”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#43A24A”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#FFFFFF”, ‘color’, ‘#FFFFFF’);
})()
More reading
Down 10%, the most valuable stock on the FTSE 100 is starting to look cheap!
2 FTSE 100 shares to buy in the UK stock market crash
2 no-brainer value stocks I think I’ll buy for Q4
If I’d invested £1,000 in AstraZeneca shares at the start of 2022, here’s what I’d have now
Mark Tovey has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.